ADCendo Website, Blog & Press Pages

ADCendo Website, Blog & Press Pages - aVenture

ADCendo - Library

adcendo.dkCrawled Oct 15, 2026

6 pages

Adce-t02 Tf/adcendo/our-science/adce-t02-tf
Key publications/adcendo/our-science/key-publications
A 2026 article by Thomas T Poulsen and coauthors reports preclinical efficacy and tolerability findings for ADCE-T02, an antibody-drug conjugate targeting tissue factor.
Our pipeline/adcendo/our-science/pipeline
Adcendo is advancing ADC candidates for solid epithelial tumors and cancers of mesenchymal origin, with three programs in clinical development and additional discovery assets progressing toward IND studies.
Our science/adcendo/our-science

6 pages

6 pages

Adcendo Appoints Dominik Mumberg, PhD, as Chief Scientific Officer/adcendo-appoints-dominik-mumberg-phd-as-chief-scientific-officer
Adcendo Appoints Michael Pehl as Chief Executive Officer/adcendo-appoints-michael-pehl-as-chief-executive-officer
Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform/adcendo-aps-announces-license-agreement-with-duality-biologics-on-next-generation-adc-platform
Adcendo Further Strengthens Management Team and Scientific Advisory Board with Appointment of International ADC Leaders/adcendo-further-strengthens-management-team-and-scientific-advisory-board-with-appointment-of-international-adc-leaders

1 page

Your careers and our values/adcendo/your-careers-and-our-values
The company aims to provide patients with medicines for underserved cancer indications.

4 pages

Board of Directors/adcendo/about/board-of-directors
Laura has been CEO of Capstan Therapeutics since September 2022, focusing on in vivo cell engineering with targeted lipid nanoparticles. She previously served as CEO of Silverback Therapeutics and President and CEO of Synthorx.
Clinical and Scientific Advisory Board/adcendo/about/clinical-and-scientific-advisory-board
Katholieke Universiteit Leuven, Chair of Clinical Advisory Board
Leadership team/adcendo/about/leadership-team
Senior Scientific Founders/adcendo/about/senior-scientific-founders
Professor Behrendt identified and cloned uPARAP cDNA with Lars Engelholm. At the Finsen Laboratory, Niels researches collagen degradation, other ECM components, and cellular receptors in cancer.

3 pages

About/adcendo/about
About Adcendo/adcendo/about/about-adcendo
Adcendo ApS is a clinical-stage biotech company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts.
Company values/adcendo/company-values
To develop breakthrough ADC therapies against hard-to-treat solid tumor & blood cancers

1 page

Contact/adcendo/contact
The listed address is c/o Symbion, Frederiksberg Nordre Fasanvej 215, 2000 Frederiksberg, Denmark, and the CVR number is DK38780093.

1 page

Homepage/
Adcendo is developing antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

3 pages

Cookie Policy/cookie-policy
The company automatically collects website interaction data, including IP addresses, browser and device details, pages visited, visit duration, and referral websites. It may also collect general location data to improve functionality and security and analyze usage.
Expanded Access Policy/expanded-access-policy
Expanded access, also called compassionate use, may allow patients with serious or immediately life-threatening conditions to receive an investigational medical product outside clinical trials when no comparable or satisfactory alternative therapies are available.
Privacy Policy/privacy-policy
The Privacy Policy explains how the company collects, uses, and protects personal data and describes users’ data rights and how to exercise them.